4D Molecular Therapeutics, Inc. $FDMT Stake Decreased by Peapod Lane Capital LLC

Peapod Lane Capital LLC lessened its holdings in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) by 16.8% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 268,024 shares of the company’s stock after selling 54,057 shares during the quarter. 4D Molecular Therapeutics accounts for 1.7% of Peapod Lane Capital LLC’s investment portfolio, making the stock its 25th biggest position. Peapod Lane Capital LLC’s holdings in 4D Molecular Therapeutics were worth $2,010,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Dynamic Technology Lab Private Ltd bought a new stake in shares of 4D Molecular Therapeutics during the first quarter valued at approximately $39,000. Wexford Capital LP acquired a new position in shares of 4D Molecular Therapeutics during the third quarter valued at approximately $41,000. Farther Finance Advisors LLC increased its stake in shares of 4D Molecular Therapeutics by 117.4% during the third quarter. Farther Finance Advisors LLC now owns 4,952 shares of the company’s stock valued at $43,000 after acquiring an additional 2,674 shares during the period. AQR Capital Management LLC acquired a new position in shares of 4D Molecular Therapeutics during the first quarter valued at approximately $46,000. Finally, Rangeley Capital LLC acquired a new position in shares of 4D Molecular Therapeutics during the second quarter valued at approximately $48,000. Institutional investors own 99.27% of the company’s stock.

4D Molecular Therapeutics Stock Performance

4D Molecular Therapeutics stock opened at $9.61 on Friday. The firm has a market cap of $490.59 million, a price-to-earnings ratio of -3.97 and a beta of 2.94. 4D Molecular Therapeutics, Inc. has a 1 year low of $3.00 and a 1 year high of $12.34. The firm’s 50 day moving average price is $9.37 and its two-hundred day moving average price is $9.49.

4D Molecular Therapeutics (NASDAQ:FDMT) last posted its quarterly earnings results on Wednesday, March 18th. The company reported $0.43 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.53) by $0.96. The firm had revenue of $85.09 million for the quarter, compared to analyst estimates of $30.86 million. 4D Molecular Therapeutics had a negative net margin of 164.43% and a negative return on equity of 31.75%. As a group, equities analysts predict that 4D Molecular Therapeutics, Inc. will post -3.71 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the stock. Barclays assumed coverage on shares of 4D Molecular Therapeutics in a research note on Wednesday, January 28th. They set an “overweight” rating and a $33.00 price objective on the stock. Royal Bank Of Canada raised their price objective on shares of 4D Molecular Therapeutics from $32.00 to $35.00 and gave the company an “outperform” rating in a research note on Thursday, March 19th. Chardan Capital reiterated a “buy” rating and set a $26.00 price objective on shares of 4D Molecular Therapeutics in a research note on Thursday, March 19th. Wall Street Zen upgraded shares of 4D Molecular Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, March 21st. Finally, HC Wainwright reiterated a “buy” rating and set a $36.00 price objective on shares of 4D Molecular Therapeutics in a research note on Friday, March 20th. Eight analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, 4D Molecular Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $31.25.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.